Epithelial Precancerous Lesions
Epithelial precancerous lesions are a group of conditions in which abnormal keratinocytes are confined to the epidermis but carry a measurable risk of progressing to invasive carcinoma, most typically cutaneous squamous cell carcinoma (cSCC). The most important clinical forms are actinic keratosis (AK), actinic cheilitis (AC), Bowen disease (cSCC in situ) and arsenical keratosis. In most cases, these lesions arise from genetic mutations that build up after long-term exposure to ultraviolet (UV) radiation or environmental toxins. If they are not detected and treated while still precancerous, the abnormal cells can break through the basement membrane, invade the dermis and potentially spread throughout the body.
At Haute-Derma, we take a comprehensive approach to precancerous skin lesions: detailed histological and dermoscopic assessment, targeted treatment based on the concept of field cancerization, and a long-term secondary prevention plan. The goal is to clear abnormal cells at the earliest stage and keep your skin healthy over the long term.
Clinical and Pathological Features in Depth
Pathogenesis and Field Cancerization
- How UV damages the skin: UVB radiation damages DNA directly by forming pyrimidine dimers, leading to mutations in the TP53 tumor suppressor gene in epidermal stem cells.
- Field cancerization: Even when only a few isolated keratotic papules are visible, the whole surrounding area of sun-exposed skin already carries many hidden genetic mutations. Treating only the visible lesions and ignoring this field leaves a high risk of new precancerous lesions or invasive cSCC.
Main Clinical Types
| Actinic keratosis (AK) | Actinic cheilitis (AC) | Bowen disease (cSCC in situ) |
|---|---|---|
| Rough papules or plaques with adherent scale on a pink or skin-colored base and ill-defined edges. Feels like sandpaper to the touch. | The border between lip and skin becomes blurred; the lip is dry, atrophic and scaly, with cracks or hazy white patches (leukoplakia). | Sharply defined red plaque with a thin keratotic or psoriasis-like scaly surface that grows slowly. |
| Sun-exposed sites: face, balding scalp, ears, forearms, backs of the hands. | Lower lip (which takes the most direct sun). | Sun-exposed or covered skin (linked to HPV or arsenic). |
| Low risk per individual lesion (usually under 1% per year); in people with many lesions, the cumulative risk of progressing to invasive cSCC is about 6–10% if left untreated. | Higher risk of transformation to cSCC than AK on the skin, with more aggressive invasion. | 3–5% progress to cSCC that invades through the basement membrane. |
Histopathology
- Keratinocyte atypia: Atypical cells with large, hyperchromatic, irregular nuclei and a raised nuclear-to-cytoplasmic ratio, with complete loss of polarity in the lower epidermis.
- KIN (keratinocytic intraepithelial neoplasia) grading:
- KIN I: Atypical cells confined to the lower third of the epidermis (early AK).
- KIN II: Atypical cells occupy the lower two-thirds of the epidermis.
- KIN III: Atypical cells span the full thickness of the epidermis, but the basement membrane is still intact (Bowen disease / cSCC in situ).
- Associated epidermal and dermal changes:
- Parakeratosis (retained nuclei) alternating with hyperkeratosis without nuclei produces the characteristic "flag sign" on the slide: parakeratosis sits over the atypical epidermis, while the follicular infundibula keep normal keratinization.
- Solar elastosis: In the upper dermis, collagen bundles degenerate into amorphous, blue-gray staining material.
Differential Diagnosis and Immunohistochemistry (IHC)
| Condition | Distinguishing histological features | Immunohistochemical (IHC) markers |
|---|---|---|
| Precancerous lesions (AK / Bowen) | Atypical keratinocytes confined to the epidermis; basement membrane fully continuous. | Ki-67 positive, extending into the upper (suprabasal) epidermis; p53 mutant pattern with diffuse staining or complete loss of expression. |
| Invasive squamous cell carcinoma (invasive cSCC) | Nests of malignant keratinocytes break through the basement membrane and invade the dermis and subcutaneous fat. | Very high Ki-67; strongly p63/p40 positive; p16 positive if HPV-related. |
| Seborrheic keratosis | Benign growth of basaloid cells with horn pseudocysts and no nuclear atypia. | Very low Ki-67 (< 1–2%), limited to the basal layer. |
| Psoriasis (psoriasis vulgaris) | Regular psoriasiform epidermal hyperplasia without atypia, diffuse loss of the granular layer and Munro microabscesses. | Ki-67 only mildly raised in the basal layer due to proliferation; normal p53 expression. |
Our Approach to Treating Epithelial Precancerous Lesions
By bringing together clinical dermatology, pathology and photodermatology technology, Haute-Derma has built a well-rounded strategy for managing precancerous lesions:
- Screening the whole cancerization field: We do not just treat individual visible lesions; we assess and treat the entire surrounding area of sun-damaged skin.
- Histological confirmation of the basement membrane: We use biopsy early to confirm that the lesion has not yet broken through the basement membrane (i.e., has not become invasive cSCC).
- Combining lesion-directed and field-directed therapy: We flexibly pair surgery or laser for individual lesions with topical immunomodulators or photodynamic therapy (PDT) for larger areas.
- Follow-up and secondary prevention: We set up a UV protection plan, restore the epidermal barrier and schedule regular checks to catch new changes early.
How We Diagnose Epithelial Precancerous Lesions at Haute-Derma
To avoid missing hidden lesions and to grade cellular atypia accurately, Haute-Derma follows a four-step diagnostic process:
- Clinical examination and skin mapping: A full-body skin check recording the site, size and number of lesions, with careful palpation to assess roughness.
- High-resolution dermoscopy: This reveals characteristic features such as the strawberry pattern, a yellow-white scaly network, red mucosal patches, or abnormal glomerular or dotted vessels.
- Full-thickness biopsy (punch or shave): Always performed when a lesion looks suspicious for invasion: rapid thickening or hardening, a raised nodule, ulceration, bleeding, pain or burning, or failure to respond to earlier treatment.
- Immunohistochemistry (IHC): p53, Ki-67 and p63 staining in KIN III / Bowen disease to assess the degree of atypia precisely and confirm that the basement membrane is intact.
How Precancerous Lesions Are Treated at Haute-Derma
Treatment at Haute-Derma is tailored to the number of lesions, the KIN grade and the size of the cancerization field:
- Lesion-directed therapy:
- Curettage and electrosurgery: Used for raised AK or Bowen lesions; removes the lesion quickly and provides tissue for pathology.
- Shave excision / microsurgery: Indicated for Bowen disease or lesions suspected of having become cSCC, with histologically clear margins (R0).
- Ultra-pulse CO2 laser ablation: Precisely removes superficial keratoses or actinic cheilitis with micron-level depth control.
- Field-directed therapy:
- Photodynamic therapy (PDT): A photosensitizer (5-ALA or MAL) is applied to the affected area, then a specific wavelength of red light selectively destroys the atypical keratinocytes while sparing healthy tissue.
- Prescription topical therapy: Cytotoxic or immunomodulating agents such as imiquimod, 5-fluorouracil (5-FU) or tirbanibulin, used according to your doctor's regimen.
- Medical chemical peel (medium-depth TCA): For large areas of heavily sun-damaged skin with numerous superficial AKs.
- Skin recovery and secondary protection:
- LED light therapy to calm post-procedure inflammation, prescription retinoids to promote normal epidermal renewal, and broad-spectrum sunscreen protecting against UVA, UVB and HEV light.
